<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445692</url>
  </required_header>
  <id_info>
    <org_study_id>2135.00</org_study_id>
    <secondary_id>NCI-2010-02116</secondary_id>
    <secondary_id>2135.00p</secondary_id>
    <secondary_id>2135</secondary_id>
    <secondary_id>2135.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00445692</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma</brief_title>
  <official_title>Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating
      patients who have undergone stem cell transplant for multiple myeloma. Biological therapies,
      such as lenalidomide and clarithromycin, may stimulate the immune system in different ways
      and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work
      in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving lenalidomide together with dexamethasone and
      clarithromycin may be an effective treatment for multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the toxicity of the use of lenalidomide/biaxin (clarithromycin)/dexamethasone as
      maintenance therapy after autologous/syngeneic transplant.

      II. Evaluate the median time to disease progression. III. Evaluate survival.

      OUTLINE:

      Patients receive clarithromycin orally (PO) twice daily (BID) and dexamethasone PO once a
      week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the
      absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide
      PO once daily (QD) on days 1-14. Courses with lenalidomide repeat every 21 days in the
      absence of disease progression or unacceptable toxicity.

      NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 10, 2007</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade IV non-hematological toxicities (except deep venous thrombosis and pulmonary emboli) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Up to 9 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>DS Stage I Plasma Cell Myeloma</condition>
  <condition>DS Stage II Plasma Cell Myeloma</condition>
  <condition>DS Stage III Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (clarithromycin, dexamethasone, lenalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive clarithromycin PO BID and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO QD on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.
NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (clarithromycin, dexamethasone, lenalidomide)</arm_group_label>
    <other_name>Abbott-56268</other_name>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (clarithromycin, dexamethasone, lenalidomide)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (clarithromycin, dexamethasone, lenalidomide)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any autologous or syngeneic patient who underwent high dose melphalan (&gt;= 140 mg/m^2)
             therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of
             multiple myeloma and did not participate in another clinical transplant trial which
             is also evaluating long-term disease free survival or survival

          -  Platelet count (transfusion independent) &gt; 50,000 cells/mm^3 and absolute granulocyte
             count &gt; 1500 cells/mm^3 for 5 calendar days after recovery from high dose therapy

          -  Patients should be between 30 days to 120 days after transplant

          -  Willingness and ability to comply with Food and Drug Administration (FDA)-mandated
             REV ASSIST Program, Celgene System for Lenalidomide Education and Prescribing Safety

          -  Signing a written informed consent form

        Exclusion Criteria:

          -  Karnofsky score less than 70

          -  A left ventricular ejection fraction less than 45% immediately pre transplant;
             patients with congestive heart disease with transplant, history of myocardial
             infarction (MI), or history of coronary artery disease

          -  Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease), serum
             glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase
             (SGPT) &gt; 2.5 x upper limit of normal

          -  Calculated by Cockcroft-Gault formula or measured serum creatinine clearance &lt; 25
             ml/minute

          -  Pregnant and/or lactating females

          -  Patients who cannot give informed consent

          -  Patients with untreated systemic infection

          -  Patients with history prior to transplant of treatment with combination therapy
             Lenalidomide/Biaxin and steroid without response

          -  Patients allergic to lenalidomide, biaxin or dexamethasone

          -  Referring physician not registered with REV ASSIST program or unwilling to oversee
             the care of the patients on study and comply with the FDA-mandated REV ASSIST Program

          -  Patients unwilling to practice adequate forms of contraception if clinically
             indicated until 30 days after stopping therapy; male patients on study need to be
             consulted to use latex condoms (even if they have had a vasectomy) every time they
             have sex with a woman who is able to have children while they are being treated and
             for 30 days after stopping drugs

          -  Patients with &gt;= grade 3 peripheral neuropathy

          -  Prior history of uncontrollable side effects to dexamethasone therapy

          -  A prior history of human immunodeficiency virus (HIV) positivity with pre-transplant
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona Holmberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>March 7, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
